M. Shaw

Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response

Hong Liu, Yu Fu, M. Lee, 2021, BMC Cancer.

A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A Southwest oncology group study

S. Rivkin, A. Haut, J. Gottlieb, 1975, Cancer.

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy

O. Tayber, B. Modrell, James I. Kim, 2022, Cancer Immunology, Immunotherapy.

TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies

T. Traore, V. Kolev, M. Okaniwa, 2022, Cancer research communications.

Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)

R. Gregory, S. Shiao, J. Gibbs, 2022, Cancer Research.

Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models

R. Gregory, V. Appleman, M. Ganno, 2022, Cancer Research.

Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.

K. Lam, Tae Won Kim, F. Ciardiello, 2014, Clinical colorectal cancer.